Publications
255
Citations
5,733
Est. group size
~40
Recurring co-author estimate
Active years
18
Publishing since 2009
Daniel Addison works in cardio-oncology, the study of how cancer treatments—especially newer immune-based therapies like checkpoint inhibitors, CAR-T cells, bispecific antibodies, and targeted drugs—affect the heart and blood vessels. His work spans clinical studies, large-scale reviews, and policy statements aimed at detecting, preventing, and managing cardiovascular problems that arise during or after cancer treatment.
Publication output grew substantially from 2017 through a peak around 2022, and has since declined somewhat through 2025-2026 (with 2026 data likely incomplete).
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Cardiotoxicity of T cell immunotherapies
Nature Reviews Cardiology · 2026
- Cardio-kidney-metabolic syndrome and prostate cancer: Prognostic significance of higher stages for cardiovascular morbidity and mortality.
Journal of Clinical Oncology · 2026
- 26-CCC-8813-ACC COMPLETE RECOVERY FROM FULMINANT PEMBROLIZUMAB-INDUCED MYOCARDITIS REQUIRING VA-ECMO SUPPORT
Journal of the American College of Cardiology · 2026
- F-83 | Elevated C- Reactive Protein Identifies a High-Risk Inflammatory Phenotype in Immune Checkpoint Inhibitor-Associated Myocarditis
Journal of the Society for Cardiovascular Angiography & Interventions · 2026
- Artificial Intelligence to Enhance Precision Medicine in Cardio-Oncology: A Scientific Statement From the American Heart Association
Circulation Genomic and Precision Medicine · 2025
- Disparities in Current Pulmonary Embolism Management and Outcomes: A Scientific Statement From the American Heart Association
Circulation · 2025
- Data Interoperability and Harmonization in Cardiovascular Genomic and Precision Medicine
Circulation Genomic and Precision Medicine · 2025
- Quality-of-Care Measures for Cardio-Oncology
JACC CardioOncology · 2025
- Major adverse cardiovascular events after teclistamab in relapsed refractory multiple myeloma: A multicenter study from the u.s. multiple myeloma immunotherapy consortium.
Blood · 2025
- CARDIOVASCULAR RISK OF BRUTON’S TYROSINE KINASE INHIBITORS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
Journal of the American College of Cardiology · 2025
- Cardiotoxicity profile of novel bispecific T-cell engager therapies
Blood · 2025
- Cardiovascular toxicities associated with novel cellular immune therapies
Blood Advances · 2024
- Response to: Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy' by Noguchi <i>et al</i>
Journal for ImmunoTherapy of Cancer · 2024
- The Influence of Outcome Prevalence on the Predictive Value of Coronary Plaque Characteristics
JACC. Cardiovascular imaging · 2024
- Cardiovascular Imaging in Contemporary Cardio-Oncology: A Scientific Statement From the American Heart Association
Circulation · 2023
- Circulation×33
- Journal of the American College of Cardiology×23
- Blood×9
- European Heart Journal×9
- Journal of the American Heart Association×9
- Yu Kang
Medicine · The Ohio State University
- Onaopepo Kola‐Kehinde
Medicine · The Ohio State University
- Avirup Guha
Medicine · The Ohio State University
- Patrick Ruz
Medicine · The Ohio State University
- Sanam Ghazi
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile